These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 7950503

  • 1. Transforming growth factor beta-induced dissociation between vitamin D receptor level and 1,25-dihydroxyvitamin D3 action in osteoblast-like cells.
    Staal A, Birkenhäger JC, Pols HA, Buurman CJ, Vink-van Wijngaarden T, Kleinekoort WM, van den Bemd GJ, van Leeuwen JP.
    Bone Miner; 1994 Jul; 26(1):27-42. PubMed ID: 7950503
    [Abstract] [Full Text] [Related]

  • 2. Antagonistic effects of transforming growth factor-beta on vitamin D3 enhancement of osteocalcin and osteopontin transcription: reduced interactions of vitamin D receptor/retinoid X receptor complexes with vitamin E response elements.
    Staal A, Van Wijnen AJ, Desai RK, Pols HA, Birkenhäger JC, Deluca HF, Denhardt DT, Stein JL, Van Leeuwen JP, Stein GS, Lian JB.
    Endocrinology; 1996 May; 137(5):2001-11. PubMed ID: 8612541
    [Abstract] [Full Text] [Related]

  • 3. Consequences of vitamin D receptor regulation for the 1,25-dihydroxyvitamin D3-induced 24-hydroxylase activity in osteoblast-like cells: initiation of the C24-oxidation pathway.
    Staal A, van den Bemd GJ, Birkenhäger JC, Pols HA, van Leeuwen JP.
    Bone; 1997 Mar; 20(3):237-43. PubMed ID: 9071474
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Regulation of osteocalcin production and bone resorption by 1,25-dihydroxyvitamin D3 in mouse long bones: interaction with the bone-derived growth factors TGF-beta and IGF-I.
    Staal A, Geertsma-Kleinekoort WM, Van Den Bemd GJ, Buurman CJ, Birkenhäger JC, Pols HA, Van Leeuwen JP.
    J Bone Miner Res; 1998 Jan; 13(1):36-43. PubMed ID: 9443788
    [Abstract] [Full Text] [Related]

  • 6. Hydrocortisone and deflazacort induce different effects on vitamin D receptor level increase produced by 1,25-dihydroxyvitamin D3 in rat osteoblast-like UMR-106 cells.
    Guerrero R, de la Piedra C, Teixeiro E, Bragado R, Traba ML.
    J Rheumatol; 2004 Jan; 31(1):167-72. PubMed ID: 14705237
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Inhibition of 1,25-dihydroxyvitamin D3 stimulated osteocalcin gene transcription by tumor necrosis factor-alpha: structural determinants within the vitamin D response element.
    Kuno H, Kurian SM, Hendy GN, White J, deLuca HF, Evans CO, Nanes MS.
    Endocrinology; 1994 Jun; 134(6):2524-31. PubMed ID: 8194478
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The activity of 22-oxacalcitriol in osteoblast-like (ROS 17/2.8) cells.
    Pernalete N, Mori T, Nishii Y, Slatopolsky E, Brown AJ.
    Endocrinology; 1991 Aug; 129(2):778-84. PubMed ID: 1649745
    [Abstract] [Full Text] [Related]

  • 12. 1alpha,25-dehydroxyvitamin D3 synergism toward transforming growth factor-beta1-induced AP-1 transcriptional activity in mouse osteoblastic cells via its nuclear receptor.
    Takeshita A, Imai K, Kato S, Kitano S, Hanazawa S.
    J Biol Chem; 1998 Jun 12; 273(24):14738-44. PubMed ID: 9614072
    [Abstract] [Full Text] [Related]

  • 13. Tumor necrosis factor alpha decreases 1,25-dihydroxyvitamin D3 receptors in osteoblastic ROS 17/2.8 cells.
    Mayur N, Lewis S, Catherwood BD, Nanes MS.
    J Bone Miner Res; 1993 Aug 12; 8(8):997-1003. PubMed ID: 8213262
    [Abstract] [Full Text] [Related]

  • 14. 1,25-dihydroxyvitamin D3-mediated transforming growth factor-beta release is impaired in cultured osteoblasts from patients with multiple pituitary hormone deficiencies.
    Sterck JG, Klein-Nulend J, Burger EH, Lips P.
    J Bone Miner Res; 1996 Mar 12; 11(3):367-76. PubMed ID: 8852947
    [Abstract] [Full Text] [Related]

  • 15. 1,25-dihydroxyvitamin D3 induction of nerve growth factor in L929 mouse fibroblasts: effect of vitamin D receptor regulation and potency of vitamin D3 analogs.
    Musiol IM, Feldman D.
    Endocrinology; 1997 Jan 12; 138(1):12-8. PubMed ID: 8977379
    [Abstract] [Full Text] [Related]

  • 16. 1 alpha,25-Dihydroxyvitamin D3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells.
    Wu Y, Haugen JD, Zinsmeister AR, Kumar R.
    Biochem Biophys Res Commun; 1997 Oct 29; 239(3):734-9. PubMed ID: 9367838
    [Abstract] [Full Text] [Related]

  • 17. Identification of 1 alpha,25-dihydroxyvitamin D3 response elements in the human transforming growth factor beta 2 gene.
    Wu Y, Craig TA, Lutz WH, Kumar R.
    Biochemistry; 1999 Mar 02; 38(9):2654-60. PubMed ID: 10052935
    [Abstract] [Full Text] [Related]

  • 18. Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization.
    van Driel M, Koedam M, Buurman CJ, Roelse M, Weyts F, Chiba H, Uitterlinden AG, Pols HA, van Leeuwen JP.
    J Cell Biochem; 2006 Oct 15; 99(3):922-35. PubMed ID: 16741965
    [Abstract] [Full Text] [Related]

  • 19. Hyperresponsiveness of vitamin D receptor gene expression to 1,25-dihydroxyvitamin D3. A new characteristic of genetic hypercalciuric stone-forming rats.
    Yao J, Kathpalia P, Bushinsky DA, Favus MJ.
    J Clin Invest; 1998 May 15; 101(10):2223-32. PubMed ID: 9593778
    [Abstract] [Full Text] [Related]

  • 20. Evidence for the functional involvement of protein kinase C in the action of 1,25-dihydroxyvitamin D3 in bone.
    van Leeuwen JP, Birkenhäger JC, van den Bemd GJ, Buurman CJ, Staal A, Bos MP, Pols HA.
    J Biol Chem; 1992 Jun 25; 267(18):12562-9. PubMed ID: 1320001
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.